Last reviewed · How we verify
Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment of CRPS, resulting in complete remission of the disease in some patients. The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this procedure, providing information into the degree of relief and which of the constellation of RSD symptoms are best alleviated by this procedure would result in the optimization of this therapy for the treatment of CRPS.
Details
| Lead sponsor | Drexel University College of Medicine |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | 2006-09 |
| Completion | 2009-11 |
Conditions
- Complex Regional Pain Syndrome
Interventions
- Ketamine
- IV NSS
- Normal Saline
Primary outcomes
- The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatment of CRPS by a 30% pain reduction post treatment — Patients will be evaluated for three months after treatment
Countries
United States